Home › New Studies Investigating the Use of KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time
 

Keywords :   


New Studies Investigating the Use of KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time

2014-11-06 15:08:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. By Year End, Data on KEYTRUDA in Seven Tumor Types Will Have Been Presented WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in November and December, data will be presented for the first time investigating the use of KEYTRUDA (pembrolizumab) the companys anti-PD-1 therapy in advanced melanoma in comparison to chemotherapy, and in relapsed/refractory classical Hodgkin Lymphoma (cHL) as well as advanced triple negative breast cancer (TNBC). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestor:Joseph Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: to the time first

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
11.05Weekly Recap: Hempel, Sherwin-Williams Top This Weeks Stories
11.05LG CHI Color Master Factory Is Awarded Patent
11.05AgriWebb raises $7.2m to fuel further innovation in sustainable beef production
11.05YouGov Unveils Americans Skincare Routines
11.05Naples Soap Company Reports Revenue Surge Amidst Tourist Season
11.05Indian Perfume Brand Eze Perfumes Enters US Market
11.05LOccitane Travel Retail Showcases Travel Retail Brand Portfolio at TFWA Asia Pacific
10.05How crops are being disaster-proofed
More »